Trastuzumab Plus R115777 in Treating Patients With Advanced or Metastatic Cancer

• Status: Completed
• Trial end date: 1969-12-31
• Target enrollment: 0
• Participant gender: All

Summary

Phase I trial to study the effectiveness of trastuzumab plus R115777 in treating patients who have advanced or metastatic cancer. Monoclonal antibodies such as trastuzumab can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining trastuzumab with R115777 may kill more tumor cells.

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: National Cancer Institute (NCI)
• Treatments: Tipifarnib; Trastuzumab

Criteria

DISEASE CHARACTERISTICS:

• Histologically or cytologically confirmed advanced or metastatic adenocarcinoma

• Expression of +1 to 3+ HER2/neu on immunohistochemical or immunocytochemistry staining

• No brain metastases unless all of the following is true:

• Previously treated

• Asymptomatic

• Stable dose of decadron

• No evidence of edema

PATIENT CHARACTERISTICS:

• Age: 18 and over

• Performance status: ECOG 0-2

• Life expectancy: At least 12 weeks

• Absolute granulocyte count at least 1,500/mm3

• Platelet count at least 100,000/mm3

• Hemoglobin at least 9.0 g/dL

• Bilirubin no greater than 1.5 mg/dL

• AST/ALT no greater than 3 times upper limit of normal (ULN) (no greater than 5 times ULN in case of liver involvement)

• Creatinine no greater than 1.5 mg/dL

• LVEF at least 50% by RVG or MUGA

• No uncontrolled unstable angina

• No history of congestive heart failure or cardiac ischemia

• Not pregnant or nursing

• Negative pregnancy test

• Fertile patients must use effective contraception

• No concurrent active infection or serious systemic disorder that would preclude study

• No allergies to imidazole compounds

PRIOR CONCURRENT THERAPY:

• No prior trastuzumab (Herceptin) No other concurrent immunotherapy

• At least 4 weeks since prior chemotherapy (6 weeks since mitomycin or nitrosoureas) and recovered

• No other concurrent chemotherapy

• No concurrent hormonal cancer therapy except LHRH agonists for prostate cancer

• No concurrent radiotherapy

• No other concurrent experimental medications